Menopausal hormone therapy (HT) is already FDA-approved for hot flashes, genitourinary symptoms, and osteoporosis prevention — but a new study hints it may also be a powerful tool for tackling the mood and sleep disruptions that plague many women during the menopause transition. In a retrospective observational study published in Menopause, researchers from NYU Grossman School of Medicine followed 260 perimenopausal and postmenopausal women who were prescribed systemic HT and found significant improvements in psychological symptoms after a mean follow-up of 4.5 months.

Women with the most severe baseline mood symptoms saw the greatest gains, and sleep scores improved alongside psychological ones. Notably, benefits were consistent regardless of antidepressant use, history of anxiety or depression, menopause stage, race, or age — suggesting broad applicability.

By the Numbers:

• Severe mood symptoms dropped from 62.3% → 24.6% after ~4.5 months of HT
• Mean improvement in psychological symptom score: -2.7 (on a 0–4 scale)
• Women with severe baseline symptoms saw the largest change: -3.85
• 96.5% of participants used transdermal estradiol

Why it matters: HT is not currently FDA-approved for mood disturbances, and no standardized treatment protocols exist for menopause-related mental health symptoms. While the study's observational design limits cause-and-effect conclusions, these findings could reshape how clinicians approach comprehensive menopause care — especially for the estimated 60–86% of women who seek medical help for symptoms.